Adsorbate Or Treating Agent Contains Nitrogen Patents (Class 424/78.12)
-
Patent number: 11801253Abstract: A method of treating and preventing secondary hyperparathyroidism in CKD by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering 25-hydroxyvitamin D3 with or without 25-hydroxyvitamin D2 and, as necessary, 1,25-dihydroxyvitamin D2 as a Vitamin D hormone replacement therapy.Type: GrantFiled: September 29, 2017Date of Patent: October 31, 2023Assignee: OPKO RENAL, LLCInventors: Charles W. Bishop, Eric J. Messner
-
Patent number: 9918970Abstract: Disclosed is a pharmaceutical composition comprising a complex between solifenacin or a pharmaceutically acceptable salt thereof and an ion exchange resin, and an acrylic based polymer.Type: GrantFiled: May 18, 2011Date of Patent: March 20, 2018Assignee: Astellas Pharma Inc.Inventors: Tatsunobu Yoshioka, Makoto Murai, Hiroaki Tasaki
-
Patent number: 9198864Abstract: A tablet comprising a coated drug-ion exchange resin complex composed of methylphenidate complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated methylphenidate-ion exchange resin complex is provided. The coated methylphenidate-ion exchange resin complex is in admixture with a polymer to form a matrix. Also provided is a tablet comprising a coated drug-ion exchange resin complex composed of dexmethylphenidate complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated dexmethylphenidate-ion exchange resin complex is provided. The coated dexmethylphenidate-ion exchange resin complex is in admixture with a polymer to form a matrix.Type: GrantFiled: June 10, 2015Date of Patent: December 1, 2015Assignee: TRIS PHARMA, INCInventors: Ketan Mehta, Yu-Hsing Tu
-
Patent number: 8802074Abstract: Polymeric compounds containing polymer backbones functionalized with ion-specific recognition elements and methods for the use of these compounds are described herein. The polymeric compounds may contain multiple types of ion-specific recognition elements depending on a specific application. The polymeric compounds can be used to remove ionic species from a solution, for example, in separations applications in which a single or multiple types of ionic species are desired to be removed from the solution.Type: GrantFiled: November 23, 2009Date of Patent: August 12, 2014Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Christopher W. Bielawski, Abdullah Aydogan, Daniel J. Coady
-
Patent number: 8545829Abstract: The present invention relates to pharmaceutical preparations for oral administration, comprising one or more active substances bound to an ion exchanger. In order to improve physical stability and acceptance, particularly in animals, a pseudoplastic gel-former thickener is included.Type: GrantFiled: May 19, 2003Date of Patent: October 1, 2013Assignee: Bayer Intellectual Property GmbHInventors: Dirk Mertin, Markus Edingloh, Gert Daube
-
Patent number: 8486428Abstract: The present invention includes methods and compositions for providing rechargeable aliphatic N-halamine polymers, monomers, copolymers additives and coatings. The rechargeable aliphatic N-halamine includes an aliphatic N-halamine compound exchangeable associated with one or more halides.Type: GrantFiled: March 27, 2006Date of Patent: July 16, 2013Assignee: Board of Regents, The University of Texas SystemInventors: Yuyu Sun, Jie Luo
-
Patent number: 8409561Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.Type: GrantFiled: August 16, 2010Date of Patent: April 2, 2013Assignee: Relypsa, Inc.Inventors: Dominique Charmot, Han-Ting Chang, Mingjun Liu, Futian Liu, Gerrit Klaerner
-
Patent number: 8404784Abstract: A novel process of manufacturing sevelamer carbonate from a polyallylamine carbonate or bicarbonate chloride salt. Process for manufacture of carbonate and/or bicarbonate salts of water insoluble polymers containing amino groups that are useful as anion binders in the gastrointestinal (GI) system. The process arranges the polyallylamine chain in a solution in such a way that the cross-linking reaction with epichlorohydrin can be controlled at a desired reaction rate.Type: GrantFiled: December 2, 2009Date of Patent: March 26, 2013Assignee: Navinta LLCInventors: Christopher N. Jobdevairakkam, Hero Velladurai
-
Patent number: 8277834Abstract: The present invention is a method of manufacturing an eye lens material having a process in which a phosphorylcholine group-containing chemical compound represented by the following formula (1) is reacted and covalently bonded onto the surface of an eye lens material wherein a chemical compound having an end amino group is introduced to said eye lens material and then the chemical compound represented by the following formula (2) or (3) is introduced through said chemical compound having an end amino group. The object of the present invention is to provide a method of manufacturing a contact lens that prevents protein adsorption.Type: GrantFiled: May 18, 2005Date of Patent: October 2, 2012Assignees: Shiseido Company, Ltd.Inventors: Yukimitsu Suda, Kazuyuki Miyazawa, Kazuhiko Ishihara
-
Patent number: 8202962Abstract: Processes for making polyesters in a polyester production facility are disclosed, that include the steps of: forming a reaction medium comprising at least one monomer that includes terephthalic acid (TPA) and/or an ester derivative of TPA; subjecting at least a portion of the reaction medium to one or more chemical reactions in the polyester production facility to thereby produce the polyester; heating at least a portion of the reaction medium via indirect heat exchange with high-pressure steam, wherein the heating causes at least a portion of the high-pressure steam to condense and thereby provide pressurized condensed water; flashing at least a portion of the pressurized condensed water to thereby produce lower-pressure steam; and heating one or more process fluid streams of the polyester production facility via indirect heat exchange with at least a portion of the lower-pressure steam, wherein the process fluid streams include any stream that is formed predominately of the reaction medium and/or the at leaType: GrantFiled: September 11, 2009Date of Patent: June 19, 2012Assignee: Grupo Petrotemex, S.A. de C.V.Inventors: Alan George Wonders, James Donald Simpson, Bruce Roger DeBruin
-
Patent number: 8198397Abstract: Integrated processes for making polyesters are disclosed, that include the steps of: (a) producing an aromatic polycarboxylic acid in a monomer production facility; (b) producing a polyester in a polyester production facility, wherein the producing of the polyester comprises the substeps of: (i) forming a polyester reaction medium comprising at least a portion of the aromatic polycarboxylic acid from the monomer production facility, (ii) subjecting at least a portion of the polyester reaction medium to one or more chemical reactions to thereby produce the polyester, (iii) heating the polyester reaction medium at one or more locations in the polyester production facility via indirect heat exchange with high-pressure steam, wherein the heating causes at least a portion of the high-pressure steam to condense and thereby provide pressurized condensed water, and (iv) flashing at least a portion of the pressurized condensed water to thereby produce lower-pressure steam; and (c) using at least a portion of the lowerType: GrantFiled: September 11, 2009Date of Patent: June 12, 2012Assignee: Grupo Petrotemex, S.A. de C.V.Inventors: Alan George Wonders, James Donald Simpson, Bruce Roger DeBruin
-
Patent number: 8158117Abstract: The present invention provides improved methods and compositions for therapeutically controlling and/or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administering to the patient an amount of a dendrimer composition effective to prevent absorption of substantial amounts of phosphate from the patient's GI tract. In a preferred version, a dose of between 2.5 and 15 grams per day is effective to prevent over 80% of phosphate present in the patient's GI tract from being absorbed. The dendrimer composition may comprise a hydrochloride, hydrobromide, hydroacetate or hydroanionic form.Type: GrantFiled: September 13, 2006Date of Patent: April 17, 2012Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Katie Beth Williams, Katarzyna Barcyka
-
Patent number: 8114393Abstract: The present invention provides improved methods and compositions for therapeutically controlling and/or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administering to the patient an amount of a dendrimer composition effective to prevent absorption of substantial amounts of phosphate from the patient's GI tract. In a preferred version, a dose of between 2.5 and 15 grams per day is effective to prevent over 80% of phosphate present in the patient's GI tract from being absorbed. The dendrimer composition may comprise a hydrocitrate, hydrochloride, hydrobromide, hydroacetate or hydroanionic form.Type: GrantFiled: October 12, 2007Date of Patent: February 14, 2012Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Katarzyna M. Barycka, Lori Plum, Julia Zella, Margaret Clagett-Dame
-
Publication number: 20120027811Abstract: This invention relates to solid formulations for the oral delivery of live microbial cells which comprise dried viable cells and small amounts of a bile acid binding agent, for example, an anion exchange resin such as cholestyramine. The presence of bile acid binding agents in the formulation significantly increases the survival of the cells in the intestinal tract and facilitates delivery of the viable cells to the intestine.Type: ApplicationFiled: January 11, 2010Publication date: February 2, 2012Applicants: Recipharmcobra Holdings Limited, Cambridge Enterprise LimitedInventors: Alexander Edwards, Nigel Slater
-
Patent number: 7854924Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.Type: GrantFiled: March 30, 2004Date of Patent: December 21, 2010Assignee: Relypsa, Inc.Inventors: Robert Alpern, Jerry Buysse, Han Ting Chang, Dominique Charmot, Michael James Cope, John Fordtran, Gerrit Klaerner, Eric Connor, Mingjun Liu, Futian Liu, Jun Shao
-
Publication number: 20100272671Abstract: Methods of treating diseases diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a biguanide and a bile acid sequestrant. Drug products including a biguanide and bile acid sequestrants in combination are also disclosed.Type: ApplicationFiled: June 16, 2010Publication date: October 28, 2010Applicant: Daiichi Sankyo, Inc.Inventor: Michael R. Jones
-
Patent number: 7815898Abstract: The present invention provides medicaments useful for reducing phosphorus serum level, especially in those subjects affected from hyperphosphatemia. More specifically, the present invention relates to pharmaceutical compositions to be administered by oral route in fasting periods, in order to absorb phosphorus compounds from fluids of the enteric tract, especially from saliva.Type: GrantFiled: November 29, 2005Date of Patent: October 19, 2010Assignee: CM&D Pharma LimitedInventor: Vincenzo Savica
-
Patent number: 7811600Abstract: Disclosed are implantable medical devices comprising nitric oxide (NO) donating polymers comprising polymer backbones having at least one cyclic amine disposed thereon. Methods are further disclosed for providing nitric oxide-donating polymers.Type: GrantFiled: March 8, 2007Date of Patent: October 12, 2010Assignee: Medtronic Vascular, Inc.Inventors: Peiwen Cheng, Mingfei Chen, Kishore Udipi
-
Publication number: 20100233116Abstract: The present invention provides heterocyclic derivatives hat modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.Type: ApplicationFiled: August 13, 2007Publication date: September 16, 2010Inventors: Natalie Dales, Julia Fonarev, Jianmin Fu, Rajender Kamboj, Vishnumurthy Kodumuru, Shifeng Liu, Natalia Pokrovskaia, Vandna Raina, Shaoyi Sun, Zaihui Zhang
-
Patent number: 7767768Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides polymeric and pharmaceutical compositions comprising crosslinked amine polymers. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of renal diseases and hyperphosphatemia.Type: GrantFiled: May 11, 2005Date of Patent: August 3, 2010Assignee: Ilypsa, Inc.Inventors: Han Ting Chang, Dominique Charmot, Eric Connor, Florence Roger
-
Publication number: 20100129309Abstract: A pharmaceutical composition for treating hyperphosphatemia can include polymers derived from multi-amine monomers and multifunctional monomers, where the multifunctional monomer includes more than one electrophilic group.Type: ApplicationFiled: February 20, 2008Publication date: May 27, 2010Inventors: Pradeep K. Dhal, Stephen Randall Holmes-Farley, Chad C. Huval, Steven C. Polomoscanik
-
Patent number: 7718746Abstract: Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described.Type: GrantFiled: May 22, 2009Date of Patent: May 18, 2010Assignee: Ilypsa, Inc.Inventors: Eric Connor, Dominique Charmot, Han-Ting Chang, Florence Roger, Gerrit Klaerner, Son Hoai Nguyen, Jonathan Mills, Jerry M. Buysse, Angela Lee, Deidre Madsen, Jun Shao, Michael J. Cope, John Fordtran
-
Publication number: 20100055066Abstract: According to the present invention, an agent for prophylactic and/or therapeutic treatment of diabetes comprising a substance inhibiting activity of farnesoid X receptor as an active ingredient can be provided.Type: ApplicationFiled: October 14, 2005Publication date: March 4, 2010Inventors: Kazuo Suzuki, Kaoru Sakai, Shinichi Ishii, Kanami Sugimoto, Johan Auwerx, Mitsuhiro Watanabe
-
Publication number: 20100021415Abstract: A cosmetic method for releasing an active principle in a controlled fashion to uninjured skin, as a function of the ion content in or on skin, by exchange with the ions, in order to provide at least one cosmetic benefit to the skin, the method includes applying onto skin a composition containing, in a cosmetically acceptable medium, at least one resinate including one organic ion-exchange resin and at least one ionizable cosmetic active principle bonded in noncovalent fashion to the resin.Type: ApplicationFiled: March 14, 2008Publication date: January 28, 2010Applicant: CHANEL PARFUMS BEAUTEInventors: Audrey Marjorie Casado-Chaudanson, Audrey Celine Marcelle Pastor
-
Patent number: 7608674Abstract: Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described.Type: GrantFiled: November 3, 2004Date of Patent: October 27, 2009Assignee: Ilypsa, Inc.Inventors: Eric Connor, Dominique Charmot, Han-Ting Chang, Florence Roger, Gerrit Klaerner, Son Hoai Nguyen, Jonathan Mills, Jerry M. Buysse, Angela Lee, Deidre Madsen, Jun Shao, Michael J. Cope, John Fordtran
-
Publication number: 20090004133Abstract: The present invention provides improved methods and compositions for therapeutically controlling and/or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administering to the patient an amount of a dendrimer composition effective to prevent absorption of substantial amounts of phosphate from the patient's GI tract. In a preferred version, a dose of between 2.5 and 15 grams per day is effective to prevent over 80% of phosphate present in the patient's GI tract from being absorbed. The dendrimer composition may comprise a hydrocitrate, hydrochloride, hydrobromide, hydroacetate or hydroanionic form.Type: ApplicationFiled: October 12, 2007Publication date: January 1, 2009Inventors: Hector F. DeLuca, Katarzyna M. Barycka, Lori Plum, Julia Zella, Margaret Clagett-Dame
-
Patent number: 7459502Abstract: Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described.Type: GrantFiled: October 13, 2004Date of Patent: December 2, 2008Assignee: Ilypsa, Inc.Inventors: Eric Connor, Dominique Charmot, Han Ting Chang, Florence Roger, Gerrit Klearner, Son Hoai Nguyen
-
Patent number: 7459151Abstract: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.Type: GrantFiled: December 6, 2005Date of Patent: December 2, 2008Assignee: Genzyme CorporationInventors: Stephen Randall Holmes-Farley, W. Harry Mandeville, III, George M. Whitesides
-
Publication number: 20080279808Abstract: The invention relates to novel compounds of general formula I wherein M represents hydrogen, or a metallic cation, preferably an alkaline metal, or alkaline-earth metal, and n is equal to 1, 2 or 3. The present invention also comprises compounds of general formula I in their equilibrium forms, including lactonic forms, their enantiomers in pure form, or in an enriched form in one of the optical isomers, racemic mixtures, diastereomers and solvates thereof. The present invention further relates to processes for the preparation of compounds of general formula I, to pharmaceutical compositions comprising compounds of general formula I as only active ingredient, or in association with other active ingredients. Another aspect of the invention is the use of compounds of general formula I for the treatment of dyslipidemia, associated, or not, to other metabolic disorders, such as glucose intolerance syndrome and type 1 or 2 diabetes mellitus, by means of isolated administration or combined with other substances.Type: ApplicationFiled: November 15, 2006Publication date: November 13, 2008Inventors: Jorge Ruas Da Silva, Ana Maria Staack Reis Machado, Joaquim Alberto Barros Pereira, Joao Carlos Ramos Damil, Carlos Alberto Casimiro Caixado, Augusto Eugenio Pardal Filipe
-
Patent number: 7385012Abstract: The present invention provides polymeric and pharmaceutical compositions comprising a polymer that contains vicinal amine moieties, referred to as polyvicinalamine polymers. The polyvicinalamines can be copolymers or homopolymers. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of renal diseases, hyperphosphatemia, and the removal of bile acids, oxalates and iron from the gastrointestinal tract.Type: GrantFiled: November 3, 2003Date of Patent: June 10, 2008Assignee: Ilypsa, Inc.Inventors: Han Ting Chang, Dominique Charmot, Samir Zard
-
Patent number: 7220406Abstract: Amine polymers, particularly aliphatic amine polymers, are useful in the treatment and prevention of bone disease and in methods for promoting bone formation. Sevelemer, polyallylamine crosslinked with epichlorohydrin, which is sold under the tradename Renagel®, is the preferred polymer used in the invention.Type: GrantFiled: October 16, 2003Date of Patent: May 22, 2007Assignee: Genzyme CorporationInventor: Steven K. Burke
-
Patent number: 7147845Abstract: The present invention relates to novel antimicrobial silver ion complex resinates. More particularly, the present invention contemplates silver ion complex resinate compositions comprising a silver-thiosulfate ion complex loaded onto an organic anion exchange resin. These silver thiosulfate ion complex resinate compositions are able to release stable antimicrobial silver ion complexes when placed in a saline environment. These antimicrobial silver-ion complex resinates are useful in the treatment and prevention of infections and diseases.Type: GrantFiled: April 14, 2004Date of Patent: December 12, 2006Assignee: BioInterface Technologies, Inc.Inventor: Christopher C. Capelli
-
Patent number: 7087223Abstract: Provided in a phosphate ion adsorbent containing a weakly basic anion exchange resin as an active ingredient which aims at providing preventives and/or remedies for hyperphosphatemia having a high selectivity for the adsorption of phosphate ion and showing an effect of lowering blood phosphorus level and another effect of suppressing phosphorus excretion into the urine.Type: GrantFiled: November 9, 2004Date of Patent: August 8, 2006Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Takeshi Goto, Kazuhisa Yoshitake, Hiroshi Sorimachi, Kazuteru Moriyama
-
Patent number: 7078050Abstract: A white cream bacteriostat and fungicide capable of serving as a vehicle for additional medicaments. Also disclosed is a method for blending the ingredients, some of which are not readily compatible with each other.Type: GrantFiled: October 25, 2004Date of Patent: July 18, 2006Inventor: Normajean Fusco
-
Patent number: 7067116Abstract: Physiologically acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer, such as pullulan, and a taste masked pharmaceutically active agent, such as dextromethorphan. The taste masking agent is preferably a sulfonated polymer ion exchange resin comprising polystyrene cross-linked with divinylbenzene, such as AMBERLITE. Methods for producing the films are also disclosed.Type: GrantFiled: March 23, 2000Date of Patent: June 27, 2006Assignee: Warner-Lambert Company LLCInventors: William S. Bess, Neema Kulkarni, Suhas H. Ambike, Michael P. Ramsay
-
Patent number: 7014846Abstract: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.Type: GrantFiled: January 28, 2004Date of Patent: March 21, 2006Assignee: Genzyme CorporationInventors: Stephen Randall Holmes-Farley, W. Harry Manderville, III, George M. Whitesides
-
Patent number: 6899868Abstract: The present invention relates to iodine demand disinfectants. It relates in particular to a process for preparing a polyiodide-resin for use as an iodine demand disinfectant wherein a porous strong base anion exchange resin in a salt form, is contacted with a material capable of donating a member absorbable by the resin so as to convert the resin to the polyiodide-resin. The adsorbable member is selected from the group comprising I2 and polyiodide ion having a valence of ?1. The process is characterized in that conversion of the anion exchange resin to the polyiodide-resin is effected at elevated temperature and elevated pressure, the elevated temperature being 100 degrees C. or higher, the elevated pressure being greater than atmospheric pressure. The present invention also relates to disinfectant substance comprising an iodine (impregnated) resin as produced by the above process.Type: GrantFiled: May 31, 2002Date of Patent: May 31, 2005Assignee: Triosyn Holding Inc.Inventor: Pierre Jean Messier
-
Patent number: 6858203Abstract: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.Type: GrantFiled: December 17, 2002Date of Patent: February 22, 2005Assignee: Genzyme CorporationInventors: Stephen Randall Holmes-Farley, W. Harry Mandeville, III, George M. Whitesides
-
Patent number: 6844372Abstract: An cross-linked anion exchange resin or a salt thereof obtained by reacting a polymer (A) having amino and/or imino groups in the total number of two or more per molecule with a compound (B) having two or more functional groups capable of reacting with amino and/or imino group contained in the polymer (A). The resin or salt has a water absorption ratio of 4.0 or lower.Type: GrantFiled: March 9, 2001Date of Patent: January 18, 2005Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Takeshi Goto, Kazuhisa Yoshitake, Kazuteru Moriyama, Shuichi Toriya, Tsutomu Yuasa, Hideyuki Nishibayashi
-
Publication number: 20040241135Abstract: The present invention relates to a resin comprising a bio-enhancer and an optional therapeutically active ingredient or precursor thereof loaded thereon. The bio-enhancer is ionizable or non-ionizable, and the resin may be a cation exchange resin or an anion exchange resin.Type: ApplicationFiled: May 27, 2004Publication date: December 2, 2004Inventor: Lyn Hughes
-
Publication number: 20040228830Abstract: A multiparticulate milnacipran composition for oral administration has been developed. The formulation is made by complexing milnacipran with an ion-exchange resin in the form of small particles, typically less than 150 microns.Type: ApplicationFiled: January 28, 2004Publication date: November 18, 2004Applicant: Collegium Pharmaceutical, Inc.Inventors: Jane Hirsh, Alison B. Fleming, Roman V. Rariy
-
Patent number: 6797259Abstract: The present invention relates to the delivery of muscle relaxants through an inhalation route. Specifically, it relates to aerosols containing a muscle relaxant that is used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of muscle relaxant. In a method aspect of the present invention, a muscle relaxant is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of a muscle relaxant, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.Type: GrantFiled: May 15, 2002Date of Patent: September 28, 2004Assignee: Alexza Molecular Delivery CorporationInventors: Joshua D. Rabinowitz, Alejandro C. Zaffaroni
-
Publication number: 20040180034Abstract: The invention provides a pharmaceutical composition that includes a non-ionizable anthlemintic drug or derivative thereof loaded onto an anion exchange resin or a cation exchange resin. The non-ionizable anthlemintic is praziquantel, a praziquantel derivative, epsiprantel, or an epsiprantel derivative. The anthlemintic can also include Droncit, a derivative of Droncit, a precursor of Droncit, Drontal, a precursor of Drontal, a derivative of Drontal, Drontal Plus, a derivative of Drontal Plus, a precursor of Drontal Plus, a formulation comprising Praziquantel and Pyrantel Pamoate, and a formulation comprising Praziquantel, Pyrantel Pamoate and/or Febantel. In another variant, the invention includes a pharmaceutical composition including a basic anthlemintic drug loaded onto an anion exchange resin, or an acidic anthlemintic drug loaded onto a cation exchange resin, and a process for manufacturing the pharmaceutical composition.Type: ApplicationFiled: February 20, 2004Publication date: September 16, 2004Inventors: Lyn Hughes, Witold Andrew Ziarno
-
Publication number: 20040105838Abstract: A pharmaceutical combination or composition containing a lipase inhibitor, preferably orlistat, and a bile acid sequestrant is useful for treating obesity.Type: ApplicationFiled: November 20, 2003Publication date: June 3, 2004Inventors: Pierre Barbier, Paul Hadvary, Hans Lengsfeld
-
Publication number: 20040091450Abstract: This disclosure relates to compositions comprising an open-celled polymeric foam wherein the compositions are useful for sequestering lipophilic materials present in the gastrointestinal tract, thereby inhibiting the absorption of such lipophilic materials by the body. The disclosure further relates to compositions comprising the open-celled polymeric foam wherein the compositions are useful for ameliorating side effects associated with the use of lipase inhibitors. In a preferred embodiment, this disclosure relates to compositions comprising polymeric foam materials made from high internal phase emulsions, where such foams are useful for sequestering lipophilic materials. Further disclosed are compositions comprising open-celled polymeric foams wherein the compositions are useful for the purpose of sequestering aqueous and/or hydrophilic materials present in the gastrointestinal tract, thereby ameliorating diarrhea.Type: ApplicationFiled: October 31, 2003Publication date: May 13, 2004Applicant: The Procter & Gamble CompanyInventors: Bryn Hird, Ronald James Jandacek
-
Patent number: 6726905Abstract: The present invention relates to a method for lowering the serum phosphate level of a patient. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer characterized by a diallylamine monomer or repeat unit. The amino nitrogen atom of the diallylamine repeat unit can be substituted by one or two substituents independently selected from among substituted and unsubstituted, normal, branched and cyclic alkyl groups, and aryl groups. When the diallylamine repeat unit comprises an ammonium or quaternary ammonium group, the monomer will further comprise a suitable anion, such as a conjugate base of a pharmaceutically acceptable acid.Type: GrantFiled: November 5, 1997Date of Patent: April 27, 2004Assignee: Genzyme CorporationInventors: W. Harry Mandeville, III, Stephen Randall Holmes-Farley
-
Patent number: 6702997Abstract: The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.63 mg or about 1.25 mg albuterol.Type: GrantFiled: December 28, 2001Date of Patent: March 9, 2004Assignee: Dey, L.P.Inventors: Imtiaz Chaudry, Partha Banerjee
-
Patent number: 6692732Abstract: A method for treating pathogenic toxins in a mammal, such as a human, comprising treating the mammal with a therapeutically effective amount of a polymer comprising a cationic group attached to the polymer backbone. The polymer can be a homopolymer or a copolymer. In one embodiment, the polymer is a copolymer comprising a monomer having a pendant ammonium group and a hydrophobic monomer.Type: GrantFiled: December 19, 2002Date of Patent: February 17, 2004Assignee: Genzyme CorporationInventors: Richard Fitzpatrick, Chad Cori Huval, Caroline Isabelle Bacon Kurtz, W. Harry Mandeville, III, Thomas X. Neenan
-
Patent number: 6680050Abstract: The present invention relates to iodine demand disinfectants. It relates in particular to a process for preparing a polyiodide-resin for use as an iodine demand disinfectant wherein a porous strong base anion exchange resin in a salt form, is contacted with a material capable of donating a member absorbable by the resin so as to convert the resin to the polyiodide-resin. The adsorbable member is selected from the group comprising I2 and polyiodide ion having a valence of −1. The process is characterized in that conversion of the anion exchange resin to the polyiodide-resin is effected at elevated temperature and elevated pressure, the elevated temperature being 100 degrees C. or higher, the elevated pressure being greater than atmospheric pressure. The present invention also relates to disinfectant substance comprising an iodine (impregnated) resin as produced by the above process.Type: GrantFiled: March 12, 1999Date of Patent: January 20, 2004Assignee: Triosyn Holdings, Inc.Inventor: Pierre Jean Messier
-
Patent number: 6673338Abstract: The invention provides NO— or NO−-releasing imidate, thioimidate, and amide diazeniumdiolates, in which the N2O2− functional group is bonded to a carbon atom. The invention also provides compositions comprising such diazeniumdiolate compounds, and methods of using such compounds and compositions. The invention further provides a method of preparing NO— or NO−-releasing imidate, thioimidate, and amide diazeniumdiolates.Type: GrantFiled: September 10, 2001Date of Patent: January 6, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Ernst V. Arnold, Larry K. Keefer, Joseph A. Hrabie